KalVista Pharmaceuticals, Inc. (KALV): Price and Financial Metrics
KALV Price/Volume Stats
| Current price | $14.86 | 52-week high | $16.88 |
| Prev. close | $14.76 | 52-week low | $6.26 |
| Day low | $14.31 | Volume | 1,210,700 |
| Day high | $15.00 | Avg. volume | 864,124 |
| 50-day MA | $12.66 | Dividend yield | N/A |
| 200-day MA | $10.35 | Market Cap | 513.55M |
KALV Stock Price Chart Interactive Chart >
KalVista Pharmaceuticals, Inc. (KALV) Company Bio
KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, discovers, develops, and commercializes small molecule protease inhibitors. The companys product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral plasma kallikrein inhibitors. The company is based in Cambridge, Massachusetts.
Latest KALV News From Around the Web
Below are the latest news stories about KALVISTA PHARMACEUTICALS INC that investors may wish to consider to help them evaluate KALV as an investment opportunity.
KalVista Pharmaceuticals Announces Publication of First Oral Factor XIIa Data in Frontiers in PharmacologyCAMBRIDGE, Mass. & SALISBURY, England, December 20, 2023--KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors today announced that data from the first report of an oral, potent, and selective FXIIa inhibitor has been published in the peer-reviewed scientific journal, Frontiers in Pharmacology. |
KALV Stock Earnings: KalVista Pharma Misses EPS for Q2 2024KALV stock results show that KalVista Pharma missed analyst estimates for earnings per share the second quarter of 2024. |
KalVista Pharmaceuticals Inc (KALV) Reports Second Fiscal Quarter ResultsAdvances in Clinical Trials and Increased R&D Expenses Mark the Quarter |
KalVista Pharmaceuticals Reports Second Fiscal Quarter Results and Provides Operational UpdateCAMBRIDGE, Mass. & SALISBURY, England, December 07, 2023--KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, today provided an operational update and released financial results for the second fiscal quarter ended October 31, 2023. |
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)CAMBRIDGE, Mass. & SALISBURY, England, December 05, 2023--KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced that the compensation committee of KalVista’s board of directors granted four newly-hired employees inducement options to purchase an aggregate of 43,000 shares of KalVista common stock on December 1, 2023 as inducements material to each employee entering into employment with KalVista. The options were granted in accordance with Nasdaq Listing Rule 5635(c)(4). |
KALV Price Returns
| 1-mo | 19.74% |
| 3-mo | 92.24% |
| 6-mo | 35.96% |
| 1-year | 83.00% |
| 3-year | -62.02% |
| 5-year | -25.70% |
| YTD | 21.31% |
| 2023 | 81.21% |
| 2022 | -48.90% |
| 2021 | -30.33% |
| 2020 | 6.63% |
| 2019 | -9.82% |
Continue Researching KALV
Want to see what other sources are saying about KalVista Pharmaceuticals Inc's financials and stock price? Try the links below:KalVista Pharmaceuticals Inc (KALV) Stock Price | Nasdaq
KalVista Pharmaceuticals Inc (KALV) Stock Quote, History and News - Yahoo Finance
KalVista Pharmaceuticals Inc (KALV) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...